Nektar Therapeutics at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
And I believe we're live, if I counted down in my head correctly. Hello, everyone, good afternoon. My name is Chris Shibutani. I'm a member of the Goldman Sachs biotech equity research team now apparently. I'm joined by my colleague, CJ Zopf. CJ, wave to your fans.
Hello there.
We're here together with Nektar Therapeutics. We're very excited to have joining us today, Jennifer Ruddock, Senior Vice President of Strategy and Corporate Affairs, different shop, but I'll continue my tradition, CFO, Gil Labrucherie, which we'll just call you Gil for short; and of course, everybody knows JZ as well, Jonathan Zalevsky, who's beaming down from his location to join us so that he can tackle all the tough questions that CJ always asks so politely.
So we're excited to get to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
